US 11,865,187 B2
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
James M. Wilson, Philadelphia, PA (US); William Thomas Rothwell, Philadelphia, PA (US); and Christian Hinderer, New Orleans, LA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed by The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed on Aug. 6, 2020, as Appl. No. 16/986,946.
Application 16/986,946 is a continuation of application No. 15/306,413, granted, now 10,780,182, previously published as PCT/US2015/027491, filed on Apr. 24, 2015.
Claims priority of provisional application 61/984,686, filed on Apr. 25, 2014.
Prior Publication US 2020/0368368 A1, Nov. 26, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 48/00 (2006.01); C07K 16/32 (2006.01); A61K 9/00 (2006.01)
CPC A61K 48/005 (2013.01) [A61K 9/0085 (2013.01); C07K 16/32 (2013.01); C07K 2317/24 (2013.01); C12N 2750/14143 (2013.01)] 16 Claims
 
1. A composition comprising at least one recombinant adeno-associated virus (rAAV) and at least one pharmaceutically acceptable carrier, preservative, and/or stabilizer, wherein the at least one rAAV comprises a vector genome in an AAV capsid,
wherein the vector genome is a nucleic acid molecule which comprises an AAV 5′ ITR, an expression cassette, and an AAV 3′ ITR,
wherein said expression cassette comprises:
(i) a coding sequence for an anti-Her2 immunoglobulin heavy chain having an IL-2 leader peptide, a heavy chain variable region having an amino acid sequence of SEQ ID NO: 18 and a heavy chain constant region,
(ii) a linker sequence,
(iii) a coding sequence for an anti-Her2 immunoglobulin light chain having an IL-2 leader peptide, a light chain variable region having an amino acid sequence of SEQ ID NO: 20, and a light chain constant region, and
(iv) regulatory sequences which direct expression of the heavy chain and the light chain, and
wherein following expression in the cell, a anti-Her2 heavy chain and the anti-Her2 light chain form an anti-Her2 antibody in vivo.